Hematoxylin and eosin (H&E) staining, Sirius Red staining, and Oil Red staining of liver tissues from mice in each group after 8 weeks of treatment with either vehicle or Kylo-0603... by Xueqin lu (22250795)

Subjects:

DIO Mice Liver Staining. by Xueqin lu (22250795)

Subjects:

Trends of peroxisome-related gene expression in liver tissue. by Xueqin lu (22250795)

Subjects:

NAS (NAFLD Activity Score) of liver tissue of mice in each group after 8 weeks of treatment with either vehicle (V) or Kylo-0603 (0.1-10 mg/kg/day). by Xueqin lu (22250795)

Subjects:

The body weight and cholesterol levels of the mice were recorded before the administration of the drug. by Xueqin lu (22250795)

Subjects:

Effect of Kylo-0603 drug on the reversal of steatosis and inhibition of fibrotic process in liver tissues of the MASH mouse models (F2 ~ 3), analyzed by SHG/TPEF microscopy combine... by Xueqin lu (22250795)

Subjects:

The structures of T3 and Kylo-0603. by Xueqin lu (22250795)

Subjects:

Synthesis process of Kylo-0603. by Xueqin lu (22250795)

Subjects:

ESI-HRMS spectra for Kylo-0603. by Xueqin lu (22250795)

Subjects:

General procedure for the synthesis of Kylo-0603. by Xueqin lu (22250795)

Subjects:

Original data (a, b, c, d) and disproportionality analysis results (ROR & IC). by Mengsi Peng (12882734)

Subjects:

Signals detection based on sex and subgroup at the SOC level utilizing two disproportionality analysis methods. by Mengsi Peng (12882734)

Subjects:

Signal detection by sex and subgroup at the PT level. by Mengsi Peng (12882734)

Subjects:

Characteristics of adolescents with T2D cases reporting ADRs to metformin in FAERS. by Mengsi Peng (12882734)

Subjects:

Flowchart of case selection process from the FAERS database. by Mengsi Peng (12882734)

Subjects:

Visual summary of metformin-associated ADRs in adolescents with T2D. by Mengsi Peng (12882734)

Subjects:

Table1_Adverse event signal mining and severe adverse event influencing factor analysis of Lumateperone based on FAERS database.docx by Yanjing Zhang (401134)

“…Background<p>Lumateperone has been approved by the Food and Drug Administration (FDA) for the treatment of schizophrenia in adults since 2019, however, there is still a lack of data report on adverse reactions in real-world settings. Conducting data mining on adverse events (AEs) associated with Lumateperone and investigating the risk factors for serious AEs can provide valuable insights for its clinical practice.…”

Estimates of average yearly citations of publications by scholars accused of scientific misconduct by retraction status and time. by Giulia Maimone (20833354)

Subjects:

Estimates of the average yearly citations per publication (including all publications) by scholar group, misconduct type, and time. by Giulia Maimone (20833354)

Subjects:

Data Sheet 1_Spatial and temporal variability in blue carbon accumulation in the largest salt marsh in British Columbia, Canada.docx by Karen E. Kohfeld (11936879)